Should I Buy ARTV? ARTV 2026 Analysis

Should You Buy Artiva Biotherapeutics Inc (ARTV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.030

1 Day change

4.13%

52 Week Range

7.360

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: momentum is still weak (MACD below zero, RSI ~39) and there are no strong catalysts or proprietary buy signals today.
For an impatient buyer, the risk/reward is unfavorable at current levels: price is still below the key pivot (4.435) with nearer downside to S1 (3.908) than upside to R1 (4.962).
Small-cap pre-revenue biotech setup + upcoming earnings (2026-02-18) can create volatility, but there’s no confirming bullish trend yet.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: Bearish-to-neutral; MACD histogram at -0.1 (below 0) indicates negative momentum, though it is contracting (selling pressure may be easing).
RSI (6): 38.844, leaning weak (not oversold), suggesting there isn’t a clear rebound signal yet.
Moving averages: Converging MAs typically indicate indecision/transition, not a confirmed uptrend.
Key levels:
- Pivot: 4.435 (stock below this in pre-market at 4.22, which is a technical headwind)
- Support: S1 3.908, then S2 3.582
- Resistance: R1 4.962, then R2 5.288
Pattern-based short-term odds (from similar candlesticks): modest bullish bias (70% chance), but the expected moves are small (+2.29% next day; +5.29% next week) and don’t override the current weak momentum.

Positive Catalysts

- Pre-market green (+1.93%) while broader market is slightly down (S&P 500 -0.07%), indicating mild relative strength today.
- Statistical pattern read suggests a modest upward drift is more likely than not over the next week.
- Upcoming earnings (2026-02-18 after hours) can act as an event catalyst if results/updates exceed expectations.

Neutral/Negative Catalysts

- No news in the recent week, meaning there’s no fresh catalyst supporting a decisive breakout.
- Technicals are not confirming a buy: MACD remains negative and price is below the pivot (4.435).
- Small-cap biotech with zero revenue reported (pre-commercial) increases reliance on funding/clinical milestones.
- Trading trends: hedge funds neutral (no significant accumulation), insiders neutral (no meaningful recent buying signal).
- Congress trading: No recent congress trading data available (no supportive signal from influential purchases/sales).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (no YoY growth; effectively pre-revenue).
Net income: -$21.528M (loss improved ~23.21% YoY, which is directionally positive).
EPS: -0.88 (worsened ~4.35% YoY), indicating per-share profitability did not improve.
Gross margin: 0 and down (-100% YoY), consistent with no revenue generation.
Overall: financials reflect an early-stage biotech profile—cash burn/losses remain the key story despite some improvement in net loss.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target change data was provided, so a recent Wall Street upgrade/downgrade narrative cannot be confirmed.
Wall Street-style pros (based on what’s available): potential event-driven upside into/around earnings and typical biotech optionality.
Wall Street-style cons: lack of revenue, ongoing losses, and weak near-term technical setup without confirming accumulation signals.

5 Analyst Rating

Wall Street analysts forecast ARTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTV is 16.5 USD with a low forecast of 10 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.870

Low

Averages

16.5

High

Current: 3.870

Low

Averages

16.5

High

Wedbush

Outperform

maintain

$18 -> $23

AI Analysis

2025-10-17

Reason

Wedbush

Price Target

$18 -> $23

AI Analysis

2025-10-17

maintain

Outperform

Reason

Wedbush raised the firm's price target on Artiva Biotherapeutics to $23 from $18 and keeps an Outperform rating on the shares. The firm notes the company announced refractory rheumatoid arthritis as the lead indication for AlloNK and announced FDA Fast Track Designation, with pivotal development possible as early as 2026 pending regulatory discussions. Importantly, the development program will feature low-dose lymphodepletion to maximize B cell depletion while minimizing adverse impacts among this patient population.

H.C. Wainwright

Emily Bodnar

Buy

initiated

$12

2025-06-11

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$12

2025-06-11

initiated

Buy

Reason

H.C. Wainwright analyst Emily Bodnar assumed coverage of Artiva Biotherapeutics with a Buy rating and $12 price target. The company's primary asset, AB-101, a nongenetically modified natural killer cell therapy being evaluated in various B-cell driven autoimmune diseases in combination with anti-CD20 monoclonal antibodies has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment, the analyst tells investors in a research note. The firm sees significant share upside potential if initial safety and translational data in B-cell driven autoimmune diseases delivered by the end of 2025 and longer follow-up efficacy data in the first half of 2025 from the company's various Phase 1/2 studies are positive.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARTV

Unlock Now

ARTV Should I Buy

ARTV Should I Buy

Should You Buy Artiva Biotherapeutics Inc (ARTV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch